CDKN2A is a cell cycle regulator whose loss of function is closely related to the progression, prognosis, and treatment of lung cancer (Kim et al., 2016; Jeong et al., 2018; Liu et al., 2020; Chakraborty et al., 2021; Gutiontov et al., 2021). Here, RGCC is linked to lung carcinoma.